Document:

csax_ex105.htm

EXHIBIT 10.5
  
 STOCK PURCHASE AGREEMENT
  
 This Stock Purchase Agreement (this “Agreement”) is made and entered into as of August 24, 2017 by and between CSA Holdings, Inc., a Nevada corporation (the “Corporation”) and James Willett, an individual (the “Purchaser”). 
  
 WHEREAS, the Purchaser is a current director of the Corporation. 
  
 NOW THEREFORE, in consideration of the premises, and the mutual covenants and conditions contained herein the parties agree as follows:
  
 1. Purchase. The Purchaser hereby purchases, and the Corporation hereby sells to the Purchaser, One Million Three Hundred Thirty-Three Thousand Three Hundred Thirty-Three (1,333,333) shares of the Corporation’s common stock, par value $0.001, (the “Shares”) for an aggregate purchase price of Forty Thousand Dollars ($40,000.00) (the “Purchase Price”).
  
 2. Consideration. Purchaser has paid and Corporation acknowledges that it has received the Purchase Price in full.
  
 3. Securities Law Compliance.
  
 3.1 Exemption From Registration. The Shares have not been registered under the Securities Act of 1933, as amended (the “1933 Act”), and are being issued to the Purchaser in reliance upon the exemption from such registration provided by Section 4(2) of the 1933 Act based on the representations and warranties made by the Purchaser herein.
  
 3.2 Restricted Securities.
  
 (a) The Purchaser hereby confirms that the Purchaser has been informed that the Shares are “restricted securities” under the 1933 Act and may not be resold or transferred unless the Shares are first registered under the federal securities laws or unless an exemption from such registration is available. Accordingly, the Purchaser hereby acknowledges that the Purchaser is prepared to hold the Shares for an indefinite period of time.
  
 (b) The Purchaser is aware of the adoption of Rule 144 by the Commission, promulgated under the 1933 Act (“Rule 144”), which permits limited public resales of securities acquired in a nonpublic offering, subject to the satisfaction of certain conditions, including, among other things, the following: (i) the availability of certain current public information about the issuer; (ii) the sale being through a broker in an unsolicited “broker’s transaction”; and (iii) the amount of securities being sold during any three (3) month period not exceeding specified limitations. The Purchaser is aware that Rule 144 is not presently available to exempt the sale of the Shares from the registration requirements of the 1933 Act. The Purchaser further represents that the Purchaser understands that at the time the Purchaser wishes to sell the Shares there may be no public market upon which to make such a sale, and that, even if such a public market exists for the common stock, the Corporation may not satisfy the current public information requirement of Rule 144 or other conditions under Rule 144 which are required of the Corporation. As a result of the foregoing, the Purchaser understands that the Purchaser may be precluded from selling the Shares under Rule 144.
  
  	 
	
	 
 
	 

  
 (c) The Purchaser represents that (i) prior to acquisition of the Shares, the Purchaser acquired sufficient information about the Corporation to reach an informed and knowledgeable decision to acquire the Shares; (ii) the Purchaser has such knowledge and experience in financial and business matters as to make the Purchaser capable of evaluating the risks of the prospective investment and to make an informed investment decision; and (iii) the Purchaser is able to bear the economic risk of the Purchaser’s investment in the Shares. 
  
 4. Notices. Any notice or other communication under this Agreement shall be in writing and shall be deemed to have been given if delivered personally or by registered or certified mail, postage prepaid, addressed to the recipient at the last known address of the recipient. Either party may designate another address in writing (or by such other method approved by the Corporation) from time to time.
  
 5. Governing Law. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard to conflict of law principles.
  
 6. Integration. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof.
  
 7. Successors. This Agreement shall be binding upon and inure to the benefit of the heirs, legal representatives, successors and permitted assigns of the parties.
  
 8. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.
  
 [Signature Page Follows]
  
  	 
	2
	 
 
	 

  
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date written above.
  
  	 
	 CORPORATION:
 CSA Holdings, Inc.
 a Nevada corporation

	  
	  

	 
	 By: /s/ Tom Sciliano                              
 Name: Tom Siciliano
 Title: President

	  
	  

	 
	 PURCHASER:

	  
	  

		 /s/ James Willett                                      
 James Willett

  
  
  	 3EX-4.2

 Exhibit 4.2 

EXECUTION VERSION 

DECIPHERA PHARMACEUTICALS, LLC 

SECOND AMENDED & RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

 

									
	 	  	 	  	 	  	Page	 
			
	1.	  	Definitions	  	 	1	 
			
	2.	  	Registration Rights	  	 	5	 
				
		  	2.1	  	Demand Registration	  	 	5	 
				
		  	2.2	  	Company Registration	  	 	6	 
				
		  	2.3	  	Underwriting Requirements	  	 	7	 
				
		  	2.4	  	Obligations of the Company	  	 	8	 
				
		  	2.5	  	Furnish Information	  	 	10	 
				
		  	2.6	  	Expenses of Registration	  	 	10	 
				
		  	2.7	  	Delay of Registration	  	 	11	 
				
		  	2.8	  	Indemnification	  	 	11	 
				
		  	2.9	  	Reports Under Exchange Act	  	 	13	 
				
		  	2.10	  	Limitations on Subsequent Registration Rights	  	 	13	 
				
		  	2.11	  	“Market Stand-off” Agreement	  	 	14	 
				
		  	2.12	  	Restrictions on Transfer	  	 	15	 
				
		  	2.13	  	Termination of Registration Rights	  	 	16	 
			
	3.	  	Information and Observer Rights	  	 	16	 
				
		  	3.1	  	Delivery of Financial Statements	  	 	16	 
				
		  	3.2	  	Inspection	  	 	18	 
				
		  	3.3	  	Observer Rights	  	 	18	 
				
		  	3.4	  	Termination of Information and Observer Rights	  	 	18	 
				
		  	3.5	  	Confidentiality	  	 	19	 
			
	4.	  	Rights to Future Stock Issuances	  	 	19	 
				
		  	4.1	  	Right of First Offer	  	 	19	 
				
		  	4.2	  	Termination	  	 	21	 
			
	5.	  	Additional Covenants	  	 	21	 
				
		  	5.1	  	Insurance	  	 	21	 
				
		  	5.2	  	Employee Agreements	  	 	21	 
				
		  	5.3	  	Employee Shares	  	 	21	 
				
		  	5.4	  	Matters Requiring Investor Director Approval	  	 	22	 
				
		  	5.5	  	Board Matters	  	 	22	 
				
		  	5.6	  	Successor Indemnification	  	 	22	 

  
 i 

									
		  	5.7	  	Expenses of Counsel	  	 	23	 
				
		  	5.8	  	Indemnification Matters	  	 	23	 
				
		  	5.9	  	Right to Conduct Activities	  	 	24	 
				
		  	5.10	  	FCPA	  	 	24	 
				
		  	5.11	  	Sale of Blocker Entity	  	 	25	 
				
		  	5.12	  	Conversion to a Corporation	  	 	26	 
				
		  	5.13	  	Termination of Covenants	  	 	26	 
			
	6.	  	Miscellaneous	  	 	26	 
				
		  	6.1	  	Successors and Assigns	  	 	26	 
				
		  	6.2	  	Governing Law	  	 	27	 
				
		  	6.3	  	Counterparts	  	 	27	 
				
		  	6.4	  	Titles and Subtitles	  	 	27	 
				
		  	6.5	  	Notices	  	 	27	 
				
		  	6.6	  	Amendments and Waivers	  	 	27	 
				
		  	6.7	  	Severability	  	 	28	 
				
		  	6.8	  	Aggregation of Shares	  	 	28	 
				
		  	6.9	  	Additional Investors	  	 	28	 
				
		  	6.10	  	Entire Agreement	  	 	29	 
				
		  	6.11	  	Dispute Resolution	  	 	29	 
				
		  	6.12	  	Delays or Omissions	  	 	29	 
				
		  	6.13	  	Acknowledgment	  	 	30	 
			
	Schedule A	  	-            Schedule of Investors	  			

  

  
 ii 

 SECOND AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 26th day of May,
2017, by and among Deciphera Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”) and the successor in interest to Deciphera Pharmaceuticals, LLC, a Kansas limited liability company, each of the investors
listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. Reference is hereby made to the Company’s Third Amended and Restated Operating Agreement, dated as of even date herewith, by
and among the parties named therein, as such agreement may be amended from time to time (the “Operating Agreement”). 

RECITALS 
 WHEREAS,
the Company and certain of the Investors entered into an Amended and Restated Investors’ Rights Agreement, dated as of December 30, 2015 (the “Prior Agreement”), in connection with the purchase by such Investors of Series
B Preferred Shares from the Company, which they now wish to amend and restate in its entirety. 
 WHEREAS, concurrently with the
execution of this Agreement, the Company and the Investors are entering into a Series C Preferred Shares Purchase Agreement (the “Purchase Agreement”) providing for the sale of Series C Preferred Shares. 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce certain of the Investors to invest funds in
the Company pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register shares of Common Stock (as defined below) issuable to the
Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in this Agreement; 

WHEREAS, subject to certain limitations not applicable hereto, the Prior Agreement may be amended pursuant to Section 6.6 of the
Prior Agreement with the written consent of (i) the Company and (ii) the holders of a majority of the Common Shares issued or issuable upon conversion of the Preferred Shares then outstanding. 

NOW, THEREFORE, the parties agree to amend and restate the Prior Agreement as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital, private equity or other investment fund or account now or
hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company or investment advisor with, such Person. 

 1.2 “Change in Control” has the meaning ascribed to such term in the Operating
Agreement. 
 1.3 “Common Stock” means Surviving Corporation Shares (as defined in the Operating Agreement) issued in
connection with the conversion of the Company from a limited liability company to a corporation as contemplated by the Operating Agreement or the common stock of the Company issued following such conversion. 

1.4 “Common Shares” means the Common Shares of the Company. 

1.5 “Competitor” means a Person engaged, directly or indirectly (including through any partnership, limited liability
company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in a business competitive with that of the Company, in the reasonable determination of the Board (as defined in the Operating Agreement), but
shall not include any financial investment firm or collective investment vehicle that, together with its Affiliates, holds an equity interest in any Competitor and has not designated (and does not hereafter designate) any person as a member of the
board of directors or a board observer of such Competitor who is also a member of the Board or a board observer of the Company. 
 1.6
“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or
liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or
final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or
(iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the
Exchange Act, or any state securities law. 
 1.7 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and
the rules and regulations promulgated thereunder. 
 1.8 “Excluded Registration” means (i) a registration relating to
the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration on Form S-8, Form S-4 or any successor form to either of the foregoing; or (iii) a
registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.9 “FOIA Party” means a Person that, in the reasonable determination of the Board, may be subject to, and thereby required
to disclose non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552 (“FOIA”), any state public records access law, any state or other jurisdiction’s laws similar in intent or
effect to FOIA, or any other similar statutory or regulatory requirement. 

  
 2 

 1.10 “Form S-1” means such form under the Securities Act as in effect on the
date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.11 “Form S-3”
means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by
the Company with the SEC. 
 1.12 “GAAP” means generally accepted accounting principles in the United States. 

1.13 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.14 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.15 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 1.16 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 1.17 “Key Employee” means each of the following: Michael D. Taylor, Ph.D., Daniel L. Flynn, Ph.D., Oliver Rosen, M.D.,
Chris Morl and Thomas Kelly. 
 1.18 “Liquidity Event” has the meaning ascribed to such term in the Operating Agreement.

 1.19 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at
least 85,000 shares of Registrable Securities (as adjusted for any share split, share dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.20 “New Securities” means any Equity Securities other than Exempted Securities (each as defined in the Operating
Agreement). 
 1.21 “Person” means any individual, corporation, partnership, trust, limited liability company, association
or other entity. 
 1.22 “Preferred Shares” means, collectively, the Series A Preferred Shares (as defined in the Operating
Agreement), Series B Preferred Shares (as defined in the Operating Agreement), and Series C Preferred Shares (as defined in the Operating Agreement). 

  
 3 

 1.23 “Principal Investor” means each of Brightstar Associates LLC
(“Brightstar”), NLV-3 Deciphera, Inc. and NLV-G Deciphera, Inc. (collectively, “New Leaf”) and SVLS-Deciphera, Inc., the SV Affiliated Assignee (as defined in the Operating Agreement) (“SVLS”), DRAGSA 14 LLC and DRAGSA
20 LLC (collectively, “Viking”), and Redmile Deciphera Holdings, Inc. (“Redmile”) and any Person to which the rights under this Agreement may be assigned by Brightstar, New Leaf, SVLS, Viking, and Redmile as the case may be,
pursuant to clause (i) or (ii) of Section 6.1 and which holds at least 85,000 Common Shares issued or issuable upon conversion of Preferred Shares (subject to appropriate adjustment for share splits, share dividends,
combinations, and other recapitalizations). 
 1.24 “Registrable Securities” means (i) the Common Stock held by the
Principal Investors; (ii) Surviving Corporation Shares issued in respect of Common Shares issued or issuable upon conversion of Preferred Shares, which issuance of Surviving Corporation Shares was in connection with the conversion of the
Company from a limited liability company to a corporation, and the Common Stock issuable or issued upon conversion of such Surviving Corporation Shares; (iii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly)
upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; and (iv) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security
that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i), (ii) and (iii) above; excluding in all cases, however, any Registrable Securities sold by a
Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to
Subsection 2.13 of this Agreement. 
 1.25 “Registrable Securities then outstanding” means the number of
shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that
are Registrable Securities. 
 1.26 “Restricted Securities” means the securities of the Company required to be notated with
the legend set forth in Subsection 2.12(b) hereof. 
 1.27 “SEC” means the Securities and Exchange Commission. 

1.28 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.29 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.30 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.31 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

  
 4 

 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the date of this Agreement or
(ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least forty percent (40%) of the Registrable Securities then outstanding (or a
lesser percentage if the reasonably anticipated aggregate offering price to the public, net of Selling Expenses, would exceed $25 million) that the Company file a Form S-1 registration statement with respect to Registrable Securities then
outstanding having an anticipated aggregate offering price to the public, net of Selling Expenses, of not less than $25 million, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the
“Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S- 1
registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders,
as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from
Holders of at least ten percent (10%) of the Registrable Securities then outstanding (or a lesser percentage if the reasonably anticipated aggregate offering price to the public, net of Selling Expenses, would exceed $5 million) that the
Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5 million, then the Company shall (i) within
ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is
given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder
to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection
2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for such registration
statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate
reorganization, 

  
 5 

 
or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as
confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect
to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right
more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such ninety (90) day period other than an
Excluded Registration. 
 (d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Subsection 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is (A) one hundred eighty (180) days after the
effective date of, a Company-initiated registration for the IPO or (B) ninety (90) days after the effective date of a Company-initiated registration that is not for the IPO, provided that the Company is actively employing in good
faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected three (3) registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to
dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b) and the content of such form is reasonably sufficient for purposes of the intended
distribution. The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate
of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration in respect of which Subsection 2.2 applied, provided that the Company is actively employing in good
faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately
preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the
Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn
registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 
 2.2 Company
Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public
offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after
such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company
shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such
registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 

  
 6 

 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by a majority in
interest of the Initiating Holders and shall be reasonably acceptable to the Company. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the managing
underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would
be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the
Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the
underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 
 (b) In connection with
any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the
Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the
Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable
discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their
sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities
that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to
by all 

  
 7 

 
such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the
nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company)
are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below twenty percent (20%) of the total number of securities included in such offering, unless such offering is
the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this
Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the
estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata
reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c) For purposes of Subsection 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the
underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included.

 2.4 Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable
Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a registration statement with
respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep
such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such
one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in
such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty
(120) day period shall be extended, if necessary, to keep the registration statement effective until the earlier of (A) all such Registrable Securities are sold or (B) once all Registrable Securities held by Brightstar that are
registered on such registration statement have been sold, all such Registrable Securities may be sold freely without limitations or restrictions as to volume or manner of sale pursuant to Rule 144, provided that the Company shall not be obligated to
keep such registration statement effective during the period provided in Subsection 2.1(d)(i) or (ii); 

  
 8 

 (b) prepare and file with the SEC such amendments and supplements to such registration
statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the selling Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any
such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering, and cause to be furnished, at the request of the selling Holders, on the date that Registrable Securities are delivered to underwriters for sale in connection with an underwritten offering
pursuant to this Agreement, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering,
addressed to the underwriters by such counsel, and (ii) a letter or letters from the independent certified public accountants of the Company, in form and substance as is customarily given by the Company’s independent certified public
accountants to underwriters in an underwritten public offering, addressed to the underwriters; 
 (f) use its commercially reasonable
efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by
the Company are then listed; 
 (g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this
Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to
such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause
the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the
accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

  
 9 

 (i) notify each selling Holder, promptly after the Company receives notice thereof, of the time
when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of
the Exchange Act. 
 2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action
pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method
of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6
Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees;
printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for the selling Holders designated by the selling Holder which holds the greatest number of Registrable
Securities included in such registration (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding
begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro
rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsections
2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that
known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to
one registration pursuant to Subsection 2.1(a) or Subsection 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis
of the number of Registrable Securities registered on their behalf. 

  
 10 

 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction
restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this Section 2: 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers,
directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the
meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in
connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(a) shall not apply
to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that
they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use
in connection with such registration. 
 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify
and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the
Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent
that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each
such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such
expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the
consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and
2.8(d) exceed the net proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder). 

  
 11 

 (c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of
the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other
indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may
be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a
reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying
party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any
party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate
losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in
connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case
(x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no
event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such 

  
 12 

 
Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful
misconduct or fraud by such Holder. 
 (e) The obligations of the Company and Holders under this Subsection 2.8 shall survive the
completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement. 

2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or
regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times
after the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially reasonable efforts to file
with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies);
(ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or
regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company
so qualifies to use such form). 
 2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the
Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that (i) would
provide to such holder the right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the
registration and offering all shares of Registrable Securities that they wish to so include; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder;
provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9. 

  
 13 

 2.11 “Market Stand-off” Agreement. Each Holder hereby agrees that it will not,
without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its Common Stock or any other equity securities under the
Securities Act on a registration statement on Form S-1 or Form S-3, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the IPO or ninety
(90) days (or such lesser time period as the underwriters in such offering may require) in the case of any registration effected pursuant to Subsection 2.1(a), 2.1(b) or 2.2 other than the IPO), or such other period as may be required to
accommodate applicable regulatory restrictions, if any, on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule
2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right,
or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock then owned by the Holder
immediately prior to the date of the final prospectus or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such
transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall apply to an offering other than the
IPO only if (a) such offering was effected pursuant to Subsection 2.1, (b) such offering is underwritten, and (c) there has not been any such non-IPO offering to which this sentence applies in the preceding six-month period.
The foregoing provisions of this Subsection 2.11 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or
the immediate family of the Holder or distributions or transfers of any shares to partners, members, stockholders, Affiliates or custodians of the Holder, provided that the trustee of the trust or the partner, member, stockholder or Affiliate, as
the case may be, agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value; and shall be applicable to the Holders only if all officers and directors are
subject to the same restrictions and the Company obtains a similar agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common
Stock of all outstanding shares of Preferred Stock). The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions
hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are
necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the
number of shares subject to such agreements. 

  
 14 

 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended solely to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate, instrument, or book entry representing
(i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger,
consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of
this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give
notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested
by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect
that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any 

  
 15 

 
other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under
the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not
require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no
consideration; or (z) with respect to any customary arrangement in connection with the deposit of Registrable Securities in a non-margin custodial account so long as such Registrable Securities are in certificated form (it being understood that
the Company may require the exchange of any such certificated securities for book-entry shares upon the IPO); provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate,
instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection
2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with
any provisions of the Securities Act. 
 2.13 Termination of Registration Rights. The right of any Holder to request registration or
inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Change in Control; 
 such
time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; provided, however, that in the case of a
Principal Investor, the termination pursuant to this Subsection 2.13(b) of such Principal Investor’s right to request registration or inclusion of Registrable Securities in any such registration pursuant to Subsections 2.1 or
2.2 shall not occur until such Principal Investor first holds of record less than one percent (1%) of the outstanding capital stock of the Company (on an as-converted basis); and 

in the case of all Holders other than the Principal Investors, the third anniversary of the IPO. 

3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board has not
reasonably determined that such Major Investor is a Competitor: 
 (a) as soon as practicable, but in any event within ninety
(90) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for
such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in Subsection 3.1(e)) for such year, with an explanation 

  
 16 

 
of any material differences between such amounts and a schedule as to the sources and applications of funds for such year, and (iii) a statement of stockholders’ equity as of the end of
such year, all such financial statements (other than the comparison referenced above) audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

(b) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements
may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, a statement showing the number of shares of each class and series of Shares (as defined in the Operating Agreement) and securities convertible into or exercisable for Shares outstanding at the end of the period, the
Common Shares issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Shares and the exchange ratio or exercise price applicable thereto, and the number of shares of issued share options and share
options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief
executive officer of the Company as being true, complete, and correct; 
 (d) as soon as practicable, but in any event within thirty
(30) days of the end of each month, an unaudited income statement for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to
normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 
 (e) as soon
as practicable, but in any event no later than thirty (30) days after the first day of each fiscal year, a budget and business plan for such fiscal year (collectively, the “Budget”), prepared on a monthly basis, including
balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; 

(f) with respect to the financial statements called for in Subsection 3.1(a), Subsection 3.1(b) and Subsection 3.1(d),
an instrument executed by the chief financial officer and chief executive officer of the Company certifying that such financial statements were prepared in accordance with GAAP consistently applied with prior practice for earlier periods (except as
otherwise set forth in Subsection 3.1(b) and Subsection 3.1(d)) and fairly present the financial condition of the Company and its results of operation for the periods specified therein; and 

(g) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major
Investor may from time to time 

  
 17 

 
reasonably request, including, for the avoidance of doubt, the Schedule of Members (as defined in the Operating Agreement); provided, however, that the Company shall not be
obligated under this Subsection 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form
acceptable to the Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

3.2 Inspection. The Company shall permit each Major Investor (provided that the Board has not reasonably determined that such
Major Investor is a Competitor), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers,
during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information
that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the
attorney-client privilege between the Company and its counsel. 
 3.3 Observer Rights. The Company shall invite one designee of each
of New Leaf, Brightstar, SVLS, and Viking to attend all meetings of the Board in a nonvoting observer capacity and, in this respect, shall give such designee copies of all notices, minutes, consents, and other materials that it provides to its
directors at the same time and in the same manner as provided to such directors; provided, however, that such representatives shall agree to hold in confidence with respect to all information so provided and shall, as a condition to
their attendance at meetings of the Board and receipt of information and materials hereunder either, at the discretion of the designating Member, (i) sign a confidentiality agreement with the Company in such form as the Company may reasonably
request or (ii) agree to abide by the obligations of confidentiality substantially similar to those in this Agreement and such Member designating such representative shall be liable to the Company for any breach of such obligations of
confidentiality by such representative; and provided further, that the Company reserves the right to withhold any information and to exclude such representatives from any meeting or portion thereof if access to such information or
attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor. 

3.4 Termination of Information and Observer Rights. The covenants set forth in Subsection 3.1, Subsection 3.2, and
Subsection 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or (ii) the closing of a Change in Control, whichever event occurs first. 

  
 18 

 3.5 Confidentiality. Each Investor agrees that such Investor will keep confidential and
will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including the Schedule of Members and any notice
of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor),
(b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any
obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the
extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Shares from such Investor, if such prospective purchaser agrees to be bound by the provisions of
this Subsection 3.5; (iii) to any existing Affiliate, partner, member, stockholder, current or prospective investor or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs
such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law or at the request of any governmental or regulatory authority,
provided that, if legally permitted, the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. In the case of (i), (ii), and (iii) in the preceding
sentence, such Investor designating such representative shall be liable to the Company for any use or disclosure of the confidential information in violation of the terms of this Agreement by its designee. 

4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it
deems appropriate, among (i) itself, (ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial ownership,” as such term is defined in Rule 13d-3
promulgated under the Exchange Act, of such Major Investor (“Investor Beneficial Owners”); provided that each such Affiliate or Investor Beneficial Owner (x) is not a Competitor or FOIA Party, unless such party’s
purchase of New Securities is otherwise consented to by the Board and (y) agrees to enter into this Agreement and each of the Operating Agreement, the Voting Agreement and Right of First Refusal and Co-Sale Agreement of even date herewith among
the Company, the Investors and the other parties named therein, as an “Investor” or “Member” as applicable under each such agreement (provided that any Competitor or FOIA Party shall not be entitled to any
rights as a Major Investor under Subsections 3.1, 3.2 and 4.1 hereof . Notwithstanding the foregoing, a Major Investor may not apportion its right of first offer to more than 20 Affiliates and/or Investor Beneficial Owners. 

(a) The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to
offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

  
 19 

 (b) By notification to the Company within twenty (20) days after the Offer Notice is given,
each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Shares then held by such Major
Investor (including all shares of Common Shares then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Shares and any other Equity Securities then held by such Major Investor) bears to the total
Common Shares then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Shares and other Equity Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major
Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the
Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors
were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Shares issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of
Preferred Shares and any other Equity Securities then held, by such Fully Exercising Investor bears to the Common Shares issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Shares
and any other Equity Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of one hundred and twenty
(120) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 

(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection
4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons
at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not
consummated within thirty (30)days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this Subsection
4.1. 
 (d) The right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined
in the Operating Agreement) (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of Series C Preferred Shares to Additional Purchasers (each as defined in the Purchase Agreement) pursuant to Subsection 1.3 of the Purchase
Agreement. 
 (e) Notwithstanding any provision hereof to the contrary, in lieu of complying with the provisions of this
Subsection 4.1, the Company may elect to give notice to 

  
 20 

 
the Major Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New Securities. Each Major Investor shall have
twenty (20) days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Major Investor, maintain such Major Investor’s percentage-ownership position, calculated as set forth
in Subsection 4.1(b) before giving effect to the issuance of such New Securities. The closing of such sale shall occur within sixty (60) days of the date notice is given to the Major Investors. 

4.2 Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or effect
(i) immediately before the consummation of the IPO or (ii) the closing of a Change in Control, whichever event occurs first. 
 5.
Additional Covenants. 
 5.1 Insurance. The Company shall use its commercially reasonable efforts to maintain Directors and
Officers liability insurance in an amount not less than $5 million and on terms and conditions satisfactory to the Board and term “key-person” insurance on Dan Flynn, each in an amount and on terms and conditions satisfactory to the Board
until such time as the Board determines that such insurance should be discontinued. The key-person policy shall name the Company as loss payee, and neither policy shall be cancelable by the Company without prior approval by the Board. 

5.2 Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged
by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement; and (ii) each Key Employee to enter
into a noncompetition and nonsolicitation agreement, substantially in the form approved by the Board. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements
or any restricted stock agreement between the Company and any employee, without the consent of a majority of the Series A Designees and the Series B Designee (each as defined in the Voting Agreement of even date herewith among the Investors and the
Company, and together, the “Preferred Directors”) then serving on the Board. 
 5.3 Employee Shares. Unless
otherwise approved by the Board, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of Equity Securities after the date hereof shall be required to execute restricted share or option
agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the
remaining shares vesting in equal quarterly installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in Subsection 2.11. In addition, unless otherwise approved by
the Board, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted
shares. 

  
 21 

 5.4 Matters Requiring Investor Director Approval. So long as the holders of Preferred
Shares are entitled to elect Preferred Directors, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board, which approval must include the affirmative vote of a majority of the Preferred
Directors then serving on the Board: 
 (a) make, or permit any subsidiary to make, any loan or advance to any Person, including, without
limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee share or option plan approved by the Board; 

(b) incur any aggregate indebtedness in excess of $3,000,000 that is not already included in a budget approved by the Board, other than trade
credit incurred in the ordinary course of business; 
 (c) otherwise enter into or be a party to any transaction with any director,
officer, employee, or Affiliate of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person (each, a “Related Party”), except for (i) transactions contemplated by
this Agreement, the Purchase Agreement, and the Transaction Agreements (as defined in the Purchase Agreement); or (ii) transactions made on an arms’ length basis in the ordinary course of business and pursuant to reasonable requirements of
the Company’s business; provided that, if any director is an Affiliate of such Related Party, such director shall recuse himself or herself from such vote; 

(d) change the principal business of the Company, enter new lines of business, or exit the current line of business; 

(e) sell, assign, license, pledge, or encumber any material technology or intellectual property of the Company, other than pursuant to
licenses granted in the ordinary course of business; or 
 (f) enter into any corporate strategic relationship involving the payment,
contribution, or assignment by the Company or to the Company of money or assets greater than $1,000,000. 
 5.5 Board Matters. Unless
otherwise determined by the vote of a majority of the directors then in office, the Board shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the directors for all reasonable out-of-pocket travel
expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board. The Board shall not establish any committee of the Board without the approval of a majority of the Preferred Directors then
serving on the Board. 
 5.6 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or
merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the
obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Operating Agreement, or elsewhere, as the case may be. 

  
 22 

 5.7 Expenses of Counsel. In the event of a transaction which is a Sale of the Company (as
defined in the Voting Agreement), the reasonable fees and disbursements, not to exceed $75,000, of one counsel for the Major Investors (“Investor Counsel”), in their capacities as stockholders, shall be borne and paid by the
Company. At the outset of considering a transaction which, if consummated would constitute a Sale of the Company, the Company shall obtain the ability to share with the Investor Counsel (and such counsel’s clients) and shall share the
confidential information (including, without limitation, the initial and all subsequent drafts of memoranda of understanding, letters of intent and other transaction documents and related noncompete, employment, consulting and other compensation
agreements and plans) pertaining to and memorializing any of the transactions which, individually or when aggregated with others would constitute the Sale of the Company. The Company shall be obligated to share (and cause the Company’s counsel
and investment bankers to share) such materials when distributed to the Company’s executives and/or any one or more of the other parties to such transaction(s). In the event that Investor Counsel deems it appropriate, in its reasonable
discretion, to enter into a joint defense agreement or other arrangement to enhance the ability of the parties to protect their communications and other reviewed materials under the attorney client privilege, the Company shall, and shall direct its
counsel to, execute and deliver to Investor Counsel and its clients such an agreement in form and substance reasonably acceptable to Investor Counsel. In the event that one or more of the other party or parties to such transactions require the
clients of Investor Counsel to enter into a confidentiality agreement and/or joint defense agreement in order to receive such information, then the Company shall share whatever information can be shared without entry into such agreement and shall,
at the same time, in good faith work expeditiously to enable Investor Counsel and its clients to negotiate and enter into the appropriate agreement(s) without undue burden to the clients of Investor Counsel. 

5.8 Indemnification Matters. The Company hereby acknowledges that one (1) or more of the directors nominated to serve on the Board
by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their Affiliates (collectively, the “Fund
Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide
indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Fund Director and shall be liable for the full amount of
all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the Operating Agreement (or any agreement between the Company and such Fund
Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for
contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund
Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such
Fund Director against the Company. 

  
 23 

 5.9 Right to Conduct Activities. The Company hereby agrees and acknowledges that each of
Brightstar, New Leaf, SVLS, Viking, and Redmile (in each case together with its Affiliates) is a professional investment fund, and as such invests in numerous portfolio companies, some of which may be deemed competitive with the Company’s
business (as currently conducted or as currently propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, (a) New Leaf shall not be liable to the Company for any claim arising out of, or based
upon, (i) the investment by New Leaf in any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of New Leaf to assist any such competitive company, whether or not such action was taken
as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company and (b) SVLS shall not be liable to the Company for any claim arising out of, or based upon,
(i) the investment by SVLS in any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of SVLS to assist any such competitive company, whether or not such action was taken as a member
of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company and (c) Viking shall not be liable to the Company for any claim arising out of, or based upon,
(i) the investment by Viking in any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of Viking to assist any such competitive company, whether or not such action was taken as a
member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability
associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the
Company. 
 5.10 FCPA. The Company represents that it shall not (and shall not permit any of its subsidiaries or affiliates or any of
its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly, to any third
party, including any Non-U.S. Official (as (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable
anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their respective activities, as well as remediate any actions taken by the Company,
its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or
anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing
systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive information and/or certifications concerning its compliance with
applicable anti-corruption 

  
 24 

 
laws. The Company shall promptly notify each Investor if the Company becomes aware of any Enforcement Action (as defined in the Purchase Agreement). The Company shall, and shall cause any direct
or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect subsidiary, whether now in existence or formed in
the future, to comply in all material respects with all applicable laws. 
 5.11 Sale of Blocker Entity. 

(a) At any time prior to a conversion of the Company into a corporation pursuant to Section 10.04 of the Operating Agreement (a
“Conversion to a Corporation”), in the event of any transfer that constitutes a Liquidity Event (any such event, for purposes of this Section 5.11, a “Blocker Event”), at the request of a Holder that is a
Blocker Entity (as defined below), the Company shall use commercially reasonable efforts to cause such transfer to be structured so that the Person that would otherwise acquire such Shares shall instead acquire a corresponding percentage of shares
in such Blocker Entity from the owner(s) thereof, in lieu of such Blocker Entity selling its Shares in the Company, and all proceeds received in connection with any such transaction shall be allocated and distributed among the Holders and any
sellers of the shares of each such Blocker Entity in such transaction so that the sellers of the shares of each such Blocker Entity receive the same proportionate amount as the applicable Blocker Entity would have received had such Blocker Entity
sold the corresponding Shares of the Company. In any such sale of shares of any Blocker Entity, (i) the selling owners of such shares of such Blocker Entity and/or their affiliates shall be solely responsible for any indemnification obligations
in favor of the purchaser of such shares to the extent attributable to liabilities or breaches of representations that relate to such Blocker Entity and (ii) such Blocker Entity and any selling owners of shares in such Blocker Entity will make
representations that such Blocker Entity has not conducted any business other than directly or indirectly holding Shares. For the avoidance of doubt, in the event that a portion of the consideration associated with a Blocker Event is contingent or
in the form of a holdback or otherwise payable following consummation of such Blocker Event, such contingent consideration shall be paid directly to the Holders and sellers of the shares of any applicable Blocker Entity. 

(b) Notwithstanding anything to the contrary in Section 5.11(a) above, if the Board reasonably and in good faith determines that a
structure of such Blocker Event not involving the sale of shares of a Blocker Entity to the purchaser as described above would be in the best interests of the Holders, then the Holders shall cooperate in good faith to utilize such different
structure to consummate the Blocker Event on the condition that the proceeds to be received by the owner(s) of such Blocker Entity (after reduction for any tax liabilities applicable to such Blocker Entity) in respect of such Blocker Event will be
in an amount not less than the amount the owner(s) of such Blocker Entity would have received in respect of a sale of shares of the Blocker Entity as described in Section 5.11(a) above. 

“Blocker Entity” means (a) any non-corporate entity whose sole assets consist, directly or indirectly, of Shares and
cash or cash equivalents or (b) any corporation whose sole assets consist of Shares, interests in a non-corporate Entity described in clause (a), and cash or cash equivalents. A Blocker Entity may not conduct any business other than directly or
indirectly holding the assets described in the prior sentence. 

  
 25 

 5.12 Conversion to a Corporation. In the case of a Conversion to a Corporation in
connection with an IPO, the Company shall structure such Conversion to a Corporation so as to include an exchange of the equity interests of any owner(s) of a Blocker Entity for shares in the new corporation in a transaction that will qualify as a
tax-deferred exchange under Section 351 or Section 368 of the Internal Revenue Code of 1986, as amended from time to time, such as a contribution or other exchange of the equity interests in such Blocker Entity or of such Blocker Entity’s
Shares or a merger of such Blocker Entity into the Corporation, in each case in exchange for shares of the Corporation the value of which is equal to the value of the Shares held by such Blocker Entity. Concurrently with a Conversion to a
Corporation, the surviving corporation shall enter into a registration right agreement in a form substantially similar to this Agreement. 

5.13 Termination of Covenants. The covenants set forth in this Section 5, except for Subsection 5.6, shall terminate
and be of no further force or effect (i) immediately before consummation of the IPO or (ii) the closing of a Change in Control, whichever event occurs first. 

6. Miscellaneous. 
 6.1
Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by an Investor to a transferee of its Shares that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate
Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 85,000 Shares (subject to appropriate adjustment for share splits, share
dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Shares with
respect to which such rights are being transferred; (y) such transferee is not a Competitor; and (z) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this
Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of Shares held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a
Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that
all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this
Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. If the Company, pursuant to Section 10.04 of the Operating Agreement,
converts to a corporation, this Agreement, and the rights and obligations of the Investors herein shall remain in full force and effect, with the references herein to equity securities of the Company as a limited liability company being read to mean
the equity securities of the Company as a corporation that are substituted therefor. 

  
 26 

 6.2 Governing Law. This Agreement shall be governed by the internal law of the State of
Delaware. 
 6.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the
recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested,
postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall
be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address,
facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy shall also be sent to Goodwin Procter, LLP, 100 Northern Ave., Boston,
Massachusetts 02210, Attention: Richard Hoffman, and if notice is given to the Stockholders, a copy shall also be given to the respective parties as set forth on Schedule A hereto. 

6.6 Amendments and Waivers. Any term of this Agreement (other than Sections 3.1, 3.2, 3.3 and 4) may be
amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Common
Shares issued or issuable upon conversion of the Preferred Shares then outstanding; provided that (a) the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object
promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); (b) any provision hereof may be waived by any waiving party on such party’s own behalf,
without the consent of any other party, (c) any amendment or waiver of Sections 1.22, 1.23, 2.11 and 2.13 shall require the consent of any Principal Investor that holds at least 1% of the Common Shares issued or
issuable upon conversion of the Preferred Shares then outstanding, and (d) any amendment or waiver of Sections 5.11 and 5.12 shall require the consent of any 

  
 27 

 
Holder that is a Blocker Entity with respect to such Holder. The terms of Sections 3.1, 3.2, 3.3 and 4 may be amended and the observance of any term of such
Subsections may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Major Investors holding a majority of the Common Shares issued or issuable upon
conversion of the Preferred Shares held by all Major Investors; provided, that (x) the right of first offer set forth in Section 4 shall not be waived with respect to a Major Investor without such Major Investor’s
consent unless such Major Investor is provided with the opportunity to purchase New Securities on similar terms and price and in proportionally similar amounts as the other Major Investors who are participating in such offering; and (y) this
Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in
the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding
the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction, so long as such waiver complies with clause (x) of this provision). The Company shall give prompt written notice of any
amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be
binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a
further or continuing waiver of any such term, condition, or provision. 
 6.7 Severability. In case any one or more of the
provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal,
or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8 Aggregation of Shares. All Common Shares issued or issuable upon conversion of the Preferred Shares held or acquired by Affiliates
shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, (a) if the Company issues additional Series C
Preferred Shares after the date hereof, any purchaser of such Series C Preferred Shares may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an
“Investor” for all purposes hereunder or (b) if the Company issues Shares after the date of this Agreement in a financing transaction approved by the holders of a majority of the Series A Preferred Shares, any purchaser of such Shares
may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors
shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

  
 28 

 6.10 Entire Agreement. This Agreement (including any Schedules hereto) constitutes the
full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the
execution and delivery of this Agreement by the Company and the undersigned Investors, the Prior Agreement shall automatically terminate and be of no further force and effect and shall be amended and restated in its entirety as set forth in this
Agreement. 
 6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the
Court of Chancery in the State of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree
not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the Court of Chancery in the State of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive,
and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from
attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such
court. 
 WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT
OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE
SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE
PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES
ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 6.12 Delays or Omissions. No delay or omission to exercise any
right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be
construed to be a waiver of or acquiescence to any such 

  
 29 

 
breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or
thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.13 Acknowledgment. The Company acknowledges that the Investors are in the business of venture capital investing and therefore review
the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any
way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. 

[Remainder of Page Intentionally Left Blank] 

  
 30 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first
written above. 
  

			
	COMPANY:
	
	DECIPHERA PHARMACEUTICALS, LLC
		
	By:	 	 /s/ Michael D. Taylor

	Name:	 	Michael D. Taylor
	Title:	 	President & CEO

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
			
	BIOCHENOMIX LLC
		
	By:	 	Biochenomix, Inc., as sole member
		
	By:	 	 /s/ Daniel L. Flynn

	Name:	 	Daniel L. Flynn
	Title:	 	Managing Member

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
			
	BRIGHTSTAR ASSOCIATES LLC
		
	By:	 	 /s/ Mark Fallon

	Name:	 	Mark Fallon
	Title:	 	Member - Board of Managers

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
			
	SVLS-Deciphera, Inc.
		
	By:	 	 /s/ Denise W. Marks

	Name:	 	Denise W. Marks
	Title:	 	Chief Financial Officer

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first
written above. 
  

			
	INVESTORS:
	
	NLV-3 DECIPHERA, INC.
		
	By:	 	 /s/ Liam T. Ratcliffe

	Name:	 	Liam T. Ratcliffe
	Title:	 	Vice President, Treasurer and Secretary
	
	NLV-G DECIPHERA, INC.
		
	By:	 	 /s/ Liam T. Ratcliffe

	Name:	 	Liam T. Ratcliffe
	Title:	 	Vice President, Treasurer and Secretary

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
			
	SPHERA GLOBAL HEALTHCARE MASTER FUND
		
	By:	 	 /s/ Michelle Ross

	Name:	 	Michelle Ross
	Title:	 	 Director of Research
 Sphera Global
Healthcare

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

			
	REDMILE DECIPHERA HOLDINGS, INC.
		
	By:	 	 /s/ Jeremy Green

	Name:	 	Jeremy Green
	Title:	 	Director

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
			
	DRAGSA 20 LLC
		
	By:	 	Viking Global Investors LP, its manager
		
	By:	 	 /s/ Matthew Bloom

	Name:	 	Matthew Bloom
	Title:	 	Authorized Signatory
	
	DRAGSA 14 LLC
		
	By:	 	Viking Global Investors LP, its manager
		
	By:	 	 /s/ Matthew Bloom

	Name:	 	Matthew Bloom
	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 SCHEDULE A 

Investors 
 NLV-3 Deciphera, Inc.

 NLV-G Deciphera, Inc. 
 New Leaf Venture Partners 

***** ****** ***** 
 * ***** ******* ***** **** 

*** ***** ** ***** 
 ****** ***** ******** 

**** ***** ******** 
 This entity does not accept 

legal notices via e-mail. 
 Brightstar Associates
LLC 
 *** **** **** ****** 
 ****** ***** ** ***** 

Attn: Gary Muller 
 Biochenomix LLC 

*** ************** ***** *** 
 ********* ** ***** 

Attn: Dan Flynn 
 SVLS-Deciphera, Inc.  

c/o SV Life Sciences 
 *** ****** ***** 

*** ********** **** ***** **** 
 ******* ** ***** 

Attn: Denise Marks 
 DRAGSA 20 LLC 

DRAGSA 14 LLC 
 c/o Viking Global Investors LP 

** ******** ****** 
 ********** ** ***** 

Redmile Deciphera Holdings, Inc. 
 *** ********* ******
***** ****** 
 *** ********** ** ***** 
 Sphera Global
Healthcare Master Fund 
 *** ******* ******* *** ***** 

*** ***** *** **** *****

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]